| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/04/2007 | US7265209 CE7-specific chimeric T cell receptor |
| 09/04/2007 | US7265203 Human cytokine receptor |
| 09/04/2007 | US7264958 Method for obtaining a purified viral preparation |
| 09/04/2007 | US7264957 Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV), proteins encoded by the polynucleic acids, vaccines based on the proteins and/or polynucleic acids, a method of protecting a pig from a PRRSV and a method of detecting a PRRSV |
| 09/04/2007 | US7264941 Diagnosing infections caused by C. pneumoniae, in pathology, in epidemiology, and as vaccine components |
| 09/04/2007 | US7264939 Method of detecting native proBNP |
| 09/04/2007 | US7264938 Method of detecting native proBNP |
| 09/04/2007 | US7264820 Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline |
| 09/04/2007 | US7264819 Administering methioninase with antibiotics (pentamidine, trimethoprim and/or sulfamethoxazole); Pneumocystis carinii (P.carinii); kits |
| 09/04/2007 | US7264818 BAV packaging regions and E1 transcriptional control regions |
| 09/04/2007 | US7264817 For use in vaccines |
| 09/04/2007 | US7264816 an isolated unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome; immunizing cats; vaccines; detecting in a sample |
| 09/04/2007 | US7264815 Cloning a DNA sequence comprising all or part of a gene encoding a Mycobacterium protein into plasmid pJAM2,introducing recombinant pJAM2 obtained into a Mycobacterium host,selecting transformed colonies of the Mycobacterium host, andcultivating the transformed colonies in medium comprising acetamide |
| 09/04/2007 | US7264814 wherein at least one non-essential gene for replication thereof is inactivated; side effect reduction |
| 09/04/2007 | US7264812 Nucleic acid sequences encoding Ostertagia ostertagi proteins and parts of such nucleic acid sequences encode an immunogenic fragment of such proteins; for use in vaccines |
| 09/04/2007 | US7264811 Purified active HCV NS2/3 protease |
| 09/04/2007 | US7264810 Scaffolds comprising epitopes and genetic engineered proteins of bacteriophages, used as vaccines, anticarcinogenic agents or antiallergens |
| 09/04/2007 | US7264809 Inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide |
| 09/04/2007 | US7264808 Synthetic peptide for neurological disorders |
| 09/04/2007 | US7264807 Administering to human therapeutically effective amount of antibody which binds to tropomyosin isoform associated with ulcerative colitis |
| 09/04/2007 | US7264806 Modified anti-CD52 antibody |
| 09/04/2007 | US7264805 Proteins with a high immunoreactivity and a method for the production thereof |
| 09/04/2007 | US7264804 Kits for detecting anti-SIRS antibodies |
| 09/04/2007 | US7264803 Methods and pharmaceutical formulations for the treatment of pulmonary hypertension |
| 09/04/2007 | US7264802 Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
| 09/04/2007 | US7264801 Antibody for use in the treatment of cancer, inflammation and immunological responses |
| 09/04/2007 | US7264799 Administering to patient before or simultaneously with surgery at least one heparinase enzyme, wherein heparinase enzyme decreases localized inflammatory response in the tissue of the patient |
| 09/04/2007 | US7264798 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus |
| 08/30/2007 | WO2007098371A2 Use of flagellin to prevent and treat gram negative bacterial infection |
| 08/30/2007 | WO2007098257A2 Hiv tev compositions and methods of use |
| 08/30/2007 | WO2007098254A2 Nanoparticles for immunotherapy |
| 08/30/2007 | WO2007098186A2 Adjuvant and vaccine compositions |
| 08/30/2007 | WO2007098113A2 Ccr3 inhibition for ocular angiogenesis and macular degeneration |
| 08/30/2007 | WO2007098093A2 Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma |
| 08/30/2007 | WO2007097980A2 Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy |
| 08/30/2007 | WO2007097961A1 Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage |
| 08/30/2007 | WO2007097934A2 Methods and compositions for using erythrocytes as carriers for delivery of drugs |
| 08/30/2007 | WO2007097820A2 Viral gene products and methods for vaccination to prevent viral associated diseases |
| 08/30/2007 | WO2007097812A2 Therapeutic anti-her2 antibody fusion polypeptides |
| 08/30/2007 | WO2007097810A2 Treatment for antiphospholipid-syndrome-related pregnancy complications |
| 08/30/2007 | WO2007097789A1 Attenuated francisella and methods of use |
| 08/30/2007 | WO2007097461A1 Antibody for treatment of hepatitis c |
| 08/30/2007 | WO2007097418A1 Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition, and diagnostic reagent |
| 08/30/2007 | WO2007097370A1 IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND |
| 08/30/2007 | WO2007097251A1 PEPTIDE VACCINE FOR INDUCING PRODUCTION OF ANTI-AMYLOID-β-PEPTIDE ANTIBODY |
| 08/30/2007 | WO2007096675A1 Immune system stimulant and process of manufacturing the same |
| 08/30/2007 | WO2007096536A1 Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii |
| 08/30/2007 | WO2007096199A2 Differential diagnostics and therapy of virally induced heart muscle disease |
| 08/30/2007 | WO2007096192A2 Production of biologically active proteins |
| 08/30/2007 | WO2007096185A1 Primate model for orthopox virus infections |
| 08/30/2007 | WO2007096149A1 Thymic stromal lympho po i et in (tslp) antibodies and uses thereof |
| 08/30/2007 | WO2007096076A2 Anti-amyloid immunogenic compositions, methods and uses |
| 08/30/2007 | WO2007095976A2 Adjuvant in the form of a lipid-modified nucleic acid |
| 08/30/2007 | WO2007095749A1 Cytotoxicity mediation of cells evidencing surface expression of trop-2 |
| 08/30/2007 | WO2007095748A1 Cancerous disease modifying antibody 141205-05 |
| 08/30/2007 | WO2007095747A1 Cytotoxicity mediation of cells evidencing surface expression of cd59 |
| 08/30/2007 | WO2007095746A1 Cancerous disease modifying antibodies |
| 08/30/2007 | WO2007095745A1 Cancerous disease modifying antibody 141205-02 |
| 08/30/2007 | WO2007095729A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 08/30/2007 | WO2007077454A3 A therapeutic composition comprising an inhibitor of an hsp 90 protein |
| 08/30/2007 | WO2007077365A3 IMMUNOGLOBULIN G (IgG) CONCENTRATE DEPLETED OF ANTI-A AND ANTI-B ANTIBODIES AND OF POLYREACTIVE IgGs |
| 08/30/2007 | WO2007071986A8 Use of whole bacterial cells (actinomycetales) for maternal administration to modulate offspring immune response |
| 08/30/2007 | WO2007054279A3 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| 08/30/2007 | WO2007052059A3 Changing th1/th2 balance in split influenza vaccines with adjuvants |
| 08/30/2007 | WO2007050606A3 Detoxified endotoxin vaccine and adjuvant and uses thereof |
| 08/30/2007 | WO2007038122A3 Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni |
| 08/30/2007 | WO2007034280A3 Composition and method for prevention of influenza |
| 08/30/2007 | WO2007022477A3 Methods and compositions to generate and control the effector profile of t cells |
| 08/30/2007 | WO2007015840A3 Reagents for the detection of phosphorylated atr kinase (ser 428/ser 2317) and uses thereof |
| 08/30/2007 | WO2007014278A3 B-cell reduction using cd37-specific and cd20-specific binding molecules |
| 08/30/2007 | WO2007010413A3 Modifed esat-6 molecules and improved vaccine strains of mycobacterium bovis bcg |
| 08/30/2007 | WO2005037856A3 Multifunctional biomaterials as scaffolds for electronic, optical, magnetic, semiconducting, and biotechnological applications |
| 08/30/2007 | US20070203327 Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substanaces |
| 08/30/2007 | US20070203325 Integrase-dirived HIV-inhibiting agents |
| 08/30/2007 | US20070203185 Therapeutical Composition Containing Dentritic Cells And Use Thereof |
| 08/30/2007 | US20070203095 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid |
| 08/30/2007 | US20070203057 Compounds and methods for modulating adhesion molecule function |
| 08/30/2007 | US20070202591 Nucleotide sequences coding streptococcal pyrogenic exotoxin A and B proteins for treatment and prevention of food poisoning, bacterial arthritis and autoimmune disorders |
| 08/30/2007 | US20070202575 Asthma; ellergy vaccine; antisense therapy; used to treat, prevent, or ameliorate the symptoms resulting from exposure to a bio-warfare agent |
| 08/30/2007 | US20070202572 Microorganisms for therapy |
| 08/30/2007 | US20070202516 Gene detection assay for improving the likelihood of an effective response to an egfr antagonist cancer therapy |
| 08/30/2007 | US20070202503 Pharmaceutical Composition Of (+)-Erythro-Mefloquine And Its Use |
| 08/30/2007 | US20070202145 Method for incorporation of bioactives into a porous hydrophobic polymer scaffold |
| 08/30/2007 | US20070202134 Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis |
| 08/30/2007 | US20070202133 BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| 08/30/2007 | US20070202132 Allergenic proteins and peptides from dog dander and uses therefor |
| 08/30/2007 | US20070202131 Use Of Mycrobacterial Vaccines In Cd4+ Or Cd8+ Lymphocyte-Deficient Mammals |
| 08/30/2007 | US20070202130 Anthrax Antigens And Methods Of Use |
| 08/30/2007 | US20070202129 Use of the neurotoxic component of a botulinum toxin for the treatment of pain associated with muscle activity or contracture |
| 08/30/2007 | US20070202128 Immunomodulatory oligonucleotides |
| 08/30/2007 | US20070202127 comprise DP178 peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein; inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells |
| 08/30/2007 | US20070202125 Inhibiting rejection of a graft |
| 08/30/2007 | US20070202124 Method for the production of purified invasin protein and use thereof |
| 08/30/2007 | US20070202123 Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids |
| 08/30/2007 | US20070202122 Non-splicing variants of gp350/220 |
| 08/30/2007 | US20070202121 SPAS-1 cancer antigen |
| 08/30/2007 | US20070202120 Yellow Fever Mosquito Deoxyribonucleoside Kinases And Its Use |
| 08/30/2007 | US20070202119 Method Of Therapy |
| 08/30/2007 | US20070202118 Novel peroxiredoxin defense system from mycobacterium tuberculosis |
| 08/30/2007 | US20070202117 Compositions and Methods Of Modulating the Immune Response |